We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$113M
1-Year Est. Return
245.92%
This Fund
S&P 500
This Quarter
Est. Return
-10.15%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$54M
(-16%)
Cap. Flow
+$18.3M
Cap. Flow
% of AUM
6.41%
Top 10 Holdings %
Top 10 Hldgs %
53.89%
Holding
37
New
6
Increased
5
Reduced
8
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$19.6M |
| 2 |
Guardant Health
GH
|
+$10.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$10.3M |
| 4 |
Lantheus
LNTH
|
+$8.78M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$4.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gossamer Bio
GOSS
|
+$8.31M |
| 2 |
MacroGenics
MGNX
|
+$6.31M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$5.68M |
| 4 |
Viridian Therapeutics
VRDN
|
+$5.59M |
| 5 |
AMRS
Amyris Inc.
AMRS
|
+$4.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.94% |
| 2 | Financials | 2.06% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$47.3B
| $25M | 8.75% |
268,000
| – | – |
|
2
Arvinas
ARVN
$614M
| $18.9M | 6.6% |
230,000
+20,000
| +10% | +$1.63M |
|
3
Repligen
RGEN
$9.46B
| $18.5M | 6.48% |
70,000
| – | – |
|
|
ISO
4
DELISTED
IsoPlexis Corporation Common Stock
ISO
| $16.3M | 5.69% |
+1,770,118
| New | +$19.6M |
|
5
Fate Therapeutics
FATE
$297M
| $15.8M | 5.52% |
270,000
| – | – |
|
6
Cogent Biosciences
COGT
$6.03B
| $12.9M | 4.5% |
1,501,591
-121,000
| -7% | -$1.05M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.5M | 4.36% |
85,000
-10,000
| -11% | -$1.55M |
|
|
8
Viridian Therapeutics
VRDN
$2.6B
| $12M | 4.18% |
604,774
-300,204
| -33% | -$5.59M |
|
|
SYRS
9
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $11.5M | 4.03% |
353,990
+10,000
| +3% | +$405K |
|
|
10
Sarepta Therapeutics
SRPT
$2.38B
| $10.8M | 3.78% |
+120,000
| New | +$10.3M |
|
|
11
Guardant Health
GH
$21.7B
| $10.5M | 3.67% |
+105,000
| New | +$10.9M |
|
12
Nuvation Bio
NUVB
$2.39B
| $10.2M | 3.56% |
1,197,152
-463,795
| -28% | -$4.26M |
|
13
IDEAYA Biosciences
IDYA
$3.85B
| $10.2M | 3.55% |
430,000
-145,940
| -25% | -$3.39M |
|
|
14
Lantheus
LNTH
$6.59B
| $9.53M | 3.33% |
+330,000
| New | +$8.78M |
|
|
SLGC
15
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $9.31M | 3.25% |
800,000
| – | – |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.2M | 3.21% |
550,000
+300,000
| +120% | +$4.92M |
|
|
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.81M | 2.73% |
185,000
| – | – |
|
18
Iovance Biotherapeutics
IOVA
$3.98B
| $7.77M | 2.72% |
406,986
| – | – |
|
19
Intellia Therapeutics
NTLA
$1.79B
| $7.69M | 2.69% |
65,000
| – | – |
|
20
Nautilus Biotechnolgy
NAUT
$115M
| $6.35M | 2.22% |
1,225,060
-274,940
| -18% | -$1.47M |
|
21
Sight Sciences
SGHT
$460M
| $6.01M | 2.1% |
342,304
| – | – |
|
|
CYPH
22
Cypherpunk Technologies Inc
CYPH
$261M
| $5.88M | 2.06% |
181,500
+61,500
| +51% | +$1.71M |
|
|
23
Gossamer Bio
GOSS
$85.7M
| $5.37M | 1.88% |
475,000
-700,000
| -60% | -$8.31M |
|
|
JNCE
24
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $4.8M | 1.68% |
+575,000
| New | +$4.74M |
|
25
Rapid Micro Biosystems
RPID
$65.7M
| $4.66M | 1.63% |
437,960
| – | – |
|
Similar funds
IA
CPA
MBC
OCM
AWA
TWS
OFP
IIM
Ally Bridge Group's Q4 2021 Portfolio in Review
As of Q4 2021, Ally Bridge Group held 37 positions worth $286M, down 16% from $340M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Ally Bridge Group deployed $18.3M of net new capital in Q4 2021, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was IsoPlexis Corporation Common Stock: 1,770,118 shares worth $16.3M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 87% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Gossamer Bio, an estimated $8.31M trimmed.
- Ally Bridge Group's largest Q4 2021 buy was IsoPlexis Corporation Common Stock: 1,770,118 shares worth $16.3M.
- Ally Bridge Group added most to IVERIC bio, Inc. Common Stock in Q4 2021, an estimated $4.92M increase.
- Ally Bridge Group's biggest Q4 2021 reduction was Gossamer Bio, cutting an estimated $8.31M.
- Ally Bridge Group fully exited Invitae Corporation in Q4 2021, selling an estimated $5.68M.
- Ally Bridge Group's ten largest holdings make up 54% of its $286M portfolio in Q4 2021.
- Ally Bridge Group opened 6 new positions and closed 7 in Q4 2021.
- Ally Bridge Group's portfolio value fell 16% quarter-over-quarter to $286M.
Based on Ally Bridge Group's 13F filing for Q4 2021, filed 14 Feb 2022.